指南与共识白血病造血干细胞移植与细胞治疗

急性髓系白血病CAR T细胞临床试验实施与报告的国际共识指南

International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML.
指南 / 共识 · Blood Adv · 2025-01-01

国际研讨会汇集儿童与成人中心的基礎/转化科学与临床研究专家,针对靶向急性髓系白血病的CAR T细胞治疗临床试验设计与报告达成共识。指南旨在统一试验设计、毒性定义、相关数据收集与报告方法,提升研究质量并促进跨试验比较。

要点

  • 靶向AML的CAR T细胞治疗伴随独特临床挑战且已发表研究报告不一致。
  • 临床试验设计、毒性定义、相关数据收集与报告方法的差异阻碍了结果比较。
  • 共识指南旨在统一报告标准以支持跨试验比较并指导后续开发。

核心结论

  • 共识指南旨在提升靶向AML的CAR T细胞研究整体质量,允许跨试验比较,并为下一阶段开发提供信息。

研究设计与样本

  • 国际研讨会汇集儿童与成人中心的基礎/转化科学及临床研究专家,讨论挑战并形成共识标准,最终产出白皮书。

主要发现

  • 早期靶向AML的CAR T细胞治疗临床经验伴随高毒性和低缓解率。
  • 临床试验设计、毒性定义、相关数据收集和报告方法的变异性阻碍了领域比较研究结果和制定最佳实践。
  • 已发表研究中未统一报告CAR T细胞基本属性和疗效与毒性的关键相关因素。

关键数值与推荐

  • 共识标准经讨论并达成一致,形成白皮书。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Early clinical experience with the use of chimeric antigen receptor (CAR) T-cell therapies for patients with acute myeloid leukemia (AML) has been beset by high rates of toxicities and low rates of response. We convened an international workshop with the goal of bringing investigators in the field of AML-directed CAR T-cell therapy together to facilitate discussion of challenges and to brainstorm potential solutions. Based on discussions at the workshop, it was evident that (1) treating and targeting AML with CAR T cells is associated with unique clinical challenges, and (2) variability in clinical trial design, definitions of toxicities, correlative data collection, and reporting methods hinders the field's ability to compare study outcomes and to develop best practices. Further, details of fundamental CAR T-cell attributes and key correlates of efficacy and toxicity were not uniformly reported in published studies, limiting understanding of barriers to success. These observations led to a concerted team effort in which experts in basic/translational science and clinical investigation from pediatric and adult centers worked together to streamline key attributes of clinical trial design and reporting. Consensus criteria were discussed and agreed upon, leading to the creation of a white paper. These guidelines aim to bolster the overall quality of AML-directed CAR T-cell research, allow for comparisons across trials, and inform the next phase of development of AML-directed CAR T-cell therapies that we hope will improve patient outcomes.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Naik S, Aplenc R, Baumeister SHC, et al. International consensus guidelines for the conduct and reporting of CAR T-cell clinical trials in AML. Blood Adv. 2025. PMID: 40829117. doi:10.1182/bloodadvances.2025017011

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。